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Abstract
T helper cells that produce IL-17 (Th17 cells) have recently been identified as the third distinct subset of effector T cells.
Emerging data suggests that Th17 cells play an important role in the pathogenesis of many liver diseases by regulating
innate immunity, adaptive immunity, and autoimmunity. In this study, we examine the role and mechanism of Th17 cells in
the pathogenesis of autoimmune hepatitis (AIH). The serum levels of IL-17 and IL-23, as well as the frequency of IL-17+ cells
in the liver, were significantly elevated in patients with AIH, compared to other chronic hepatitis and healthy controls. The
hepatic expressions of IL-17, IL-23, ROR-ct, IL-6 and IL-1b in patients with AIH were also significantly increased and were
associated with increased inflammation and fibrosis. IL-17 induces IL-6 expression via the MAPK signaling pathway in
hepatocytes, which, in turn, may further stimulate Th17 cells and forms a positive feedback loop. In conclusion, Th17 cells
are key effector T cells that regulate the pathogenesis of AIH, via induction of MAPK dependent hepatic IL-6 expression.
Blocking the signaling pathway and interrupting the positive feedback loop are potential therapeutic targets for
autoimmune hepatitis.
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Introduction
Autoimmune hepatitis (AIH) is an inflammatory liver condition
characterized by interface hepatitis, hypergammaglobulinemia,
serum autoantibodies, and satisfactory response to immunosup-
pressive treatment [1], [2]. Immune reactions against host liver
antigens are believed to be a major pathogenic mechanism. The
histological feature of interface hepatitis, with the infiltration of
lymphocytes, plasma cells, and macrophages, suggests an aggres-
sive cellular immune response in the pathogenesis of AIH [3].
Immunohistochemical studies have identified the predominant T
lymphocyte infiltration as CD4
+ helper/inducer T cells and CD8+
T cells [4]. Following their activation, naı ¨ve CD4
+ T cells
differentiate into distinct T helper cell lineages, including pro-
inflammatory Th1 cells, anti-inflammatory Th2 cells, regulatory T
cells (Tregs) and newly defined Th17 cells [5]. Autoimmune
hepatitis has been associated with predominating Th1 responses
and decreased frequency and function of Tregs [6], [7].
The recently identified Th17 cells are CD4+ T cells
characterized by the secretion of IL-17 [8]. The cytokine
transforming growth factor–b (TGF-b), in the presence of
interleukin-6 (IL-6), promotes the differentiation of naı ¨ve T
lymphocytes into Th17 cells, which promote autoimmunity and
inflammation [9]. Since liver is known to be an important source
of TGF-b and IL-6, Th17 differentiation may be favored in the
liver. In fact, Th17 cells have been found to be involved in primary
biliary cirrhosis [10] and alcoholic liver disease [11], injuries
known to result from increased levels of TGF-b and IL-6. In
contrast, little is known about the role of Th17 cells on the
pathogenesis of AIH, though, deletion of Th17 has been shown to
reduce T cell mediated hepatitis [12]. The aim of the current study
is to investigate whether Th17 cells and/or the IL-17 signaling
pathway play a role in the pathogenesis of AIH. Additionally, this
study examines the potential mechanisms that underline Th17
mediated liver inflammation in AIH. Results from this study may
have profound therapeutic implications for the management of
autoimmune liver disease.
Materials and Methods
Patients and samples
Patients who satisfied the international pretreatment criteria for
the definitive diagnosis of autoimmune hepatitis (AIH) type I were
included in the study, in addition to patients with chronic hepatitis
B (CHB) and healthy volunteers. All participants gave written
informed consent for the study that was approved by the Ethics
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Peripheral blood samples from 29 AIH patients, 18 CHB patients
and 28 healthy controls; liver biopsy samples from 39 patients, 32
CHB patients and 5 healthy controls and fresh frozen liver tissue
from 28 AIH patients, 12 CHB patients and 5 healthy were
included in the study. The characterization of participants is
shown in Table 1. Peripheral blood mononuclear cells (PBMCs)
were isolated using a Ficoll separation (Ficoll-Paque plus;
Amersham Bioscience, Shanghai, China). PBMCs were then
labeled with direct fluorescent conjugated anti-human antibodies
against CD3, CD4, CD25, CCR4 and CCR6 (BD Pharmingen,
San Diego, CA). PBMCs were evaluated by flow cytometry
(Calibur, Becton Dickinson), and the data were analyzed using
Cell Quest software (Becton Dickinson). Serum IL-17A and IL-23
(p19/p40) were measured by ELISA (eBioscience, San Diego,
USA). Total RNA was extracted from biopsy samples using
Trizol reagent (Invitrogen, Carlsbad, CA, USA). Complementary
DNA was synthesized from 0.5 mg of total RNA using oligo(dT)
as the template and the RevertAid
TM First Strand cDNA
Synthesis Kit (Fermentas, Canada). Real-time PCRs were
performed using SyBR Premix Ex Taq TM (Takara) in a Roche
LightCycler 480. Negative controls were performed without
cDNA in the reaction mixture. The results were normalized
against glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
gene expression. The primer sequences for IL-17, IL-23 (p19),
IL-21, IL1-B, IL-6 and GAPDH are described in Table 2. Liver
biospies were fixed in 10% neutral buffered formalin, embedded
in paraffin, and 4 mm thick sections were cut from each paraffin
block. The slides were stained with hematoxylin-eosin, and
inflammatory degree and fibrotic stages were determined
according to the Scheuer score system. For immunohistochem-
istry, the sections were pre-incubated with 5% bovine serum
albumin for 10 min, and then incubated with anti-human IL-17
antibody (1:50 dilution, R&D systems, Minneapolis, MN, USA)
for 12 hours at 4uC in a wet chamber. After washing with
phosphate buffer saline (PBS), the sections were incubated with
an anti-goat secondary antibody (Zhongshan Golden Bridge
Biotech, Beijing, China) for 20 min at room temperature, and
detected with diaminobenzidine (DAB) and hematoxylin as the
counter stain. For immunofluorescent staining, liver specimens
were incubated with antibodies for CD4 (Shanghai Changdao
Biotech, Shanghai, China) and IL-17 (R&D), and imaged with
confocal microscopy (Leica TCS SP5II, Wetzlar, Germany).
Cell culture and ELISA assay
Human hepatoma HepG2 cells were cultured in DMEM with
10% fetal bovine serum (complete medium). At 70% confluence,
the complete medium was replaced with media containing 0.5%
FBS. After overnight incubation (quiescent cells), IL-17 (with a
final concentration of 1, 10, and 100 ng/ml) was added and the
cells were cultured for an additional 12, 24 or 48 hours. At the end
of the experiment, culture media were collected and IL-6 and
monocyte chemotactic peptide-1 (MCP-1) in the media was
determined with a standard ELISA according to the manufactur-
er’s instructions (R&D Systems, Minneapolis, MN, USA). For
kinase inhibition experiments, HepG2 cells were pretreated with
specific inhibitors to p38 MAPK (SB203580), p42/p44 ERK
(PD98059 and U0126) and JNK (SP600125) (Calbiochem,
Schwalbach, Germany), for 30 min before IL-17 (100 ng/ml)
was added to the media. The cells were cultured for an additional
48 hours.
Western Blotting
Total protein extractions were made from HepG2 cells using
a protein extraction kit (Beyotime Institute of Biotechnology).
The protein concentration was determined by the BCA assay
(Beyotime Institute of Biotechnology). Aliquots containing
30 mg of protein were subjected to electrophoresis in 10%
SDS-PAGE, followed by transfer to nitrocellulose membranes.
The membranes were blocked with 5% nonfat dry milk in Tris-
buffered saline (TBST), 0.1% Tween 20 for 1 h at room
temperature, and then incubated overnight at 4uCw i t h
antibodies specific against phosphorylated ERK1/2, p38
MAPK, JNK (Cell Signaling Technology, Beverly, MA,
Table 1. Characterization of the Study Participants.
Healthy Control (HC, n=28) Chronic Hepatitis B (CHB, n=32) Autoimmune Hepatitis (AIH, n=39)
Sex (female/male) 22/6 25/7 32/7
Age (years) 49 (22–58) 45 (18–60) 51 (18–64)
ALT 19 (9–31) 68 (18–242) 72 (24–238)
AST 27 (11–45) 62 (21–248) 68 (26–225)
Histological Findings
Inflammation (1/2/3/4) NA 7/14/10/1 2/20/15/2
Fibrosis (0/1/2/3/4) NA 9/6/4/5/8 5/8/6/14/6
Data is shown as media and range. ALT: alanine aminotransferase; AST: aspartate aminotransferase. There is no statistical difference between all three groups in sex, age.
There is no statistical difference between CHB and AIH groups in serum transaminases and histological findings.
doi:10.1371/journal.pone.0018909.t001
Table 2. The primers sequences of Th17 cells related genes
and GAPDH.
Gene Forward primer Reverse primer
IL-17 TGTCCACCATGTGGCCTAAGAG GTCCGAAATGAGGCTGTCTTTGA
IL-23
(p19)
CCAAGGACTCAGGGACAACA ATCAGGGAGCAGAGAAGGCT
IL-21 GCCACATGATTAGAATGCGTCAAC TGGAGCTGGCAGAAATTCAGG
IL-1b GCTGATGGCCCTAAACAGATGAA TGAAGCCCTTGCTGTAGTGGTG
RORct CATCTCCAGCCTCAGCTTTGA CATCTCCAGCCTCAGCTTTGA
IL-6 AAGCCAGAGCTGTGCAGATGAGTA TGTCCTGCAGCCACTGGTTC
GAPDH GAAGGTGAAGGTCGGAGTC GAAGATGGTGATGGGATTTC
For each sample, mRNA expression level was normalized to the level of GAPDH
housekeeping genes using the DDCt algorithm.
doi:10.1371/journal.pone.0018909.t002
Interleukin 17 and Autoimmune Hepatitis
PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e18909USA). After extensive washing, the blots were incubated with a
secondary antibody and signals were detected with an ECL
detection kit (Pierce, Rockford,I L ,U S A ) .T h em e m b r a n e sw e r e
then stripped and re-probed with an antibody against total
ERK, p38 MAPK and JNK. The ratio of the expression levels
of the phosphorylated ERK1/2, p38 MAPK, JNK to those of
total ERK, p38 MAPK, JNK were taken to represent their
activity, respectively. b-actin expression was determined as
loading controls.
Statistical analysis
All values are expressed as mean 6 SD. Correlations were
determined by Spearman’s correlation coefficient (SPSS13.0). The
group means were compared by t-test using Microsoft Excel
(Microsoft, Redmond, WA). P values of less than 0.05 were
considered statistically significant.
Results
Increased IL-17 and IL-23 levels and Th17 cell frequency
in the peripheral blood of patients with AIH
Th17 cells are characterized by producing large quantities of
IL-17A (also called IL-17) that is attributed to most Th17 cell-
mediated effects. IL-23 plays a critical role in the expansion and
stabilization of Th17 cells in vitro and in vivo. To determine whether
Th17 cells play a role in the pathogenesis of AIH, we first
evaluated serum IL-17 and IL-23 (p19/p40) levels, and the relative
frequency of Th17 cells in the peripheral blood of patients with
AIH, CHB and healthy controls. We found that plasma IL-17 and
IL-23 levels were significantly increased in patients with AIH,
compare to those in healthy controls or patients with CHB
(Figure 1A). There was no difference in plasma IL-17 and IL-23
levels between patients with CHB and healthy controls.
Figure 1. Blood samples were obtained from healthy controls (HC, n=28), chronic hepatitis B (CHB, n=18) and autoimmune
hepatitis (AIH, n=29) patients. Peripheral blood mononuclear cells (PBMCs) were isolated, labeled with fluorescent antibodies against CD4, CD25,
CCR4 and CCR6, and analyzed by flow cytometry. (A) Plasma IL-17 and IL-23 levels. (B) Representative dot plots; and (C) Mean (6SD) percentage of
Th17 (CD4
+CD25
2 CCR4
+CCR6
+) cells in PBMC. Panel B and C are gated on CD4
+CD25
2 cells. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0018909.g001
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+ Tc e l l
populations was determined by flow cytometry. We defined Th17
cells as CCR4
+CCR6
+CD4
+CD25
2 T cells according to previous
study [13]. There was a significant increase in Th17 cells among
PBMCs from AIH patients, compared to those from healthy
control or CHB patients (Figure 1B, C). These results indicate
that there is an expanded Th17 cell population and an increased
IL-17 level in the peripheral blood of AIH patients compared to
normal individuals, as well as patients with other chronic
hepatitis.
Figure 2. Liver biopsies were obtained from patients with either autoimmune hepatitis (AIH, n=39) or chronic hepatitis B (CHB,
n=32). Th17 cells in the liver were evaluated by immunohistochemical staining of IL-17. (A) Representative histology of Th17 cells (IL-17+, brown
stained cells, 4006); (B) Mean (6SD) of Th17 cells in AIH and CHB patients; (C) Mean (6SD) of hepatic inflammatory scores of AIH and CHB patients;
(D) Confocal staining of CD4 (in green), IL-17 (in red) and DAPI (for nuclei in blue) in the liver of AIH patients. The frequency of Th17 cells in the liver is
positively correlated with hepatic inflammatory degrees (E) and fibrosis grades (F) in AIH patients.
doi:10.1371/journal.pone.0018909.g002
Figure 3. Liver tissue were obtained from healthy controls (HC, n=5), chronic hepatitis B (CHB, n=12) and autoimmune hepatitis
(AIH, n=28) patients. Th17 related cytokines RORct, IL-17, IL-1b, IL-6, IL-21 and IL-23 expressions were determined by quantitative RT-PCR and
normalized with GAPDH expression. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0018909.g003
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AIH patients
To confirm that Th17 cells play an important role in the
pathogenesis of AIH, we further investigated the distribution and
frequency of Th17 cells in the liver by immunohistochemical
staining of IL-17. As expected, there were very few IL-17
+ cells in
the normal livers (data not shown). There were significantly
increased IL-17
+ cells in AIH patients, compared to those with
CHB (Figure 2A, B), while no difference of hepatic inflammatory
degrees between AIH and CHB patients was found (Figure 2C).
Most IL-17
+ cells in AIH patients were localized in the portal
tracts and lobular areas of the liver, among lymphoid infiltration.
Cofocal staining showed that most IL-17
+ cells are CD4
+ Tc e l l s
in AIH (Figure 2D), suggesting that Th17 cells are major source
of IL-17 in the liver. The degree of hepatic Th17 cell infiltration
was positively correlated to the degree of hepatic inflammation
and the stage of hepatic fibrosis in AIH patients (Figure 2E, F).
These results indicate that the infiltration of TH17 cells likely
contribute to hepatic inflammation and disease progression in
AIH.
The function of Th17 cells relies on their ability to secret IL-17,
IL-21, IL-22, IL-6 and TNFa, and their differentiation depends on
specific transcription nuclear factor ROR-ct [14]. To confirm the
role of Th17 cells in AIH, we evaluated Th17 cell related cytokine
expressions in the liver using real-time PCR. Th17 cell related
gene expressions of RORct, IL-17, IL-23, IL-21, IL-1b, IL-6 were
significantly increased in the liver of AIH patients compared to
those with CHB and healthy controls (Figure 3).
IL-17 induced IL-6 secretion in HepG2 cells through
MAPK signaling pathway
IL-6, in conjunction with TGF-b, promotes the generation of
Th17 cells [15], while IL-17 can also stimulate IL-6 production
[16]. During the liver inflammatory processes, hepatocytes are one
source of IL-6 secretion in the liver in addition to monocytes and
inflammatory cells [17]. We hypothesized that there is a positive-
feedback loop between Th17 cells and hepatocytes through IL-6
and IL-17 interaction. To test this hypothesis, IL-17 was added to
the culture medium for HepG2 cells. Although IL-17 had no effect
on the growth or the differentiation of HepG2 cells, even at a high
dose (data not shown), it stimulated IL-6 secretion by HepG2 cells
in dose- and time-dependent manners (Figure 4A).
MAPK, ERK and JNK signaling pathways are major signaling
pathways in the hepatic inflammatory process. They also regulate
expression and secretion of IL-6 [18]. Previous study shows that
IL-17 can activate MAPK and ERK pathway in hepatocytes [19].
To evaluate whether IL-17 stimulated IL-6 secretion in hepato-
cytes is MAPK pathway dependant, activation of MAPK, ERK
and JNK in HepG2 cells was determined after IL-17 stimulation.
IL-17 significantly enhanced the phosphorylation of MAPK, ERK
and JNK in HepaG2 cells (Figure 4B), which indicate their
activation. We then treated HepaG2 cells with specific inhibitors
of p38 MAPK (SB203580), p42/p44 ERK (PD98059 and U0126)
and JNK (SP600125) during IL-17 stimulation. All these specific
inhibitors significantly attenuated IL-6 production by HepaG2
(Figure 4C). These results indicate that IL-17 induced IL-6
production in HepaG2 cells depends on activation of MAPK,
ERK and JNK signaling pathways.
MCP-1 is a chemokine which activate and chemotactically
attract monocytes/macrophages [20]. MCP-1 expression on
hepatocytes and monocytes is increased in chronic liver diseases
[21]. In our study, IL-17 did not induce MCP-1 expression of
HepaG2 cells in a time- and dose-dependent manner (Figure 4D),
suggesting that the effect of IL-17 on IL-6 expression of HepaG2
may be a specific process.
Discussion
Immune reactions against host liver antigens are believed to be
the major mechanism resulting in AIH. A specific autoantigenic
peptide is presented to an uncommitted T helper (Th0)
lymphocyte within the HLA class II molecule of an antigen-
presenting cell (APC). Th0 cells, upon activation and expansion,
develop into different T helper cell subsets (e.g. Th1 or Th2 cells)
with different cytokine profiles and distinct effector function [3].
Th17 cells, a new T helper subset that produces IL-17, are distinct
from Th1 and Th2 cells in phenotype, function, and develop-
mental pathways [14]. Th17 cells are involved in host defense,
inflammatory disease, tumor genesis, autoimmune disease, and
transplant rejection through secretion of IL-17, IL-6, and other
cytokines [14]. IL-17 is a pro-inflammatory cytokine that induces
fibroblasts, endothelial cells, macrophages, and epithelial cells to
produce other cytokines (including IL-6) and chemokines that
mediate tissue infiltration and destruction. Also, IL-6, in
conjunction with TGF-b, promotes the further generation of
Th17 cells [15]. Th17 cells have been implemented in the
pathogenesis of some liver diseases [5], but their role in AIH is less
clear. In our current study, we have shown that the frequencies of
Th17 cells in peripheral blood and liver of AIH patients were
significantly increased compared to those of patients with other
chronic inflammatory hepatitis. Furthermore, the frequency of
Th17 cells is correlated with degrees of hepatic inflammation and
fibrosis in AIH patients. The emerging data suggest that Th17 cells
may also play an important role in liver inflammation. Liver
infiltration with IL-17 secreting cells is a key feature of alcoholic
hepatitis [11]. Serum Th17-related cytokines and IL-17+ lympho-
cytic infiltration in liver were significantly increased in patients
with primary biliary cirrhosis (PBC) [22]. Most recently, Zhang J
et al showed that Th-17 cells are increased in both peripheral blood
and livers of CHB patients, and may exacerbate liver injury during
chronic HBV infection [23]. Our study demonstrates that Th-17
cells are involved in both CHB and AIH. However, the
frequencies of peripheral and hepatic Th17 cells are much higher
in AIH patients compared to CHB patients.
In our study, we demonstrated IL-17 increases the production
of IL-6 by hepatocytes, which, in turn, further stimulates Th17
cells and provides a positive feedback loop between Th17 cells and
hepatocytes exacerbating the inflammatory process. It demonstrates
that Th17 cell proliferation is the key trigger in the pathogenesis of
AIH. In fact, it has been shown that Th17 cells play a crucial role in
the pathogenesis of some autoimmune diseases, such as collagen-
induced arthritis (CIA) and experimental autoimmune encephalo-
myelitis (EAE) [24], [25]. Accordingly, higher levels of IL-17
Figure 4. (A) IL-17 was added to HepG2 cell culture. IL-6 production by HepG2 cells in the media was measured by ELISA. (B) Total protein extract
was made from HepG2 cells after stimulated with IL-17 (100 ng/ml). Western bolts were performed with antibodies specific against phosphorylated
ERK1/2, p38 MAPK, JNK. The membranes were then stripped and re-probed with an antibody to total ERK, p38 MAPK and JNK. b-actin expression was
determined as loading controls. (C) Specific inhibitors of MAPK signaling pathways (SB203580 for MAPK, PD98059 and U0126 for ERK, SP600125 for
JNK, and DMSO as the carrier) were added to HepG2 cell culture before IL-17 stimulation. IL-6 in the media was measured by ELISA. (D) IL-17 was
added to HepG2 cell culture. MCP-1 production by HepG2 cells in the media was measured by ELISA.
doi:10.1371/journal.pone.0018909.g004
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inflammatory bowel disease (IBD) [27], and systemic lupus
erythematosus (SLE) [28]. As shown in this study, neutralization
of IL-17 may provide a potential therapeutic target for AIH.
Recently, it has been proposed that a numerical or functional
imbalance between Th17 and regulatory T cells (Tregs) may be
responsible for the development of autoimmune disease. Tregs are
a group of T cells that engage in a variety of immune suppressive
responses, including transplant tolerance [29], viral hepatitis [30],
and autoimmune hepatitis [6]. Tregs are usually CD4
+/CD25
+
and express forkhead box protein 3 (Foxp3), a specific marker and
the key factor in Treg development and function [31]. Intrigu-
ingly, there is a reciprocal relationship between Th17 cells and
Tregs in both developmental pathways and function [9]. TGF-b
can induce both anti-inflammatory Treg and pro-inflammatory
Th17 depending on the local cytokine milieu. TGF-b alone can
promote the expression of Foxp3 and induce the differentiation of
Treg cells. The frequency of Foxp3+ cells generated in the
presence of TGF-b is inversely related to the levels of IL-6, such
that Foxp3+ cells were nearly extinguished in the presence of
exogenous IL-6 [9]. IL-6 synergizes with TGF-b to promote the
expression of RORct, favoring Th17 differentiation. Thus, IL-6
acts as a key immunomodulator of TGF-b signaling, leading to the
reciprocal differentiation of Treg and Th17. It has been
demonstrated that patients with AIH have a significantly lower
frequency of Treg cells at diagnosis and the frequency increases
during remission on immunosuppression [6], [7], [30]. There is an
inverse relationship between the percentage of Treg cells and the
severity of AIH [6], [7], [30]. Our study demonstrated that IL-17
may induce hepatic IL-6 expression in AIH, which may favor
proliferation of Th-17 cells while reducing the development of
Tregs. Therefore, it reveals a potential mechanism that is critical
in the pathogenesis of AIH by tipping the balance between Th17
and Treg cells.
In conclusion, Th17 cells and the IL-17 signaling pathway play
a critical role in the pathogenesis of AIH. Restoring the imbalance
among Th17 cells and Tregs by interrupting interaction between
IL-17 and IL-6 may be an effective therapeutic target for
autoimmune liver diseases.
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